Lower Mortality with Rechanneling vs. Medical Therapy

We had to wait for it, but we have finally seen a benefit in hard endpoints—such as mortality—derived from rechanneling. Patients with chronic total occlusion (CTO) in whom rechanneling was used as initial strategy showed higher survival rated compared with those receiving medical therapy.

Menor mortalidad con las recanalizaciones vs tratamiento médico

As initial treatment strategy, rechanneling a CTO did not show any benefit in medium-term hard endpoints compared with optimal medical therapy. This recent paper published in JAHA needed a 10-year follow-up to gather this information.

Between 2003 and 2012, 2024 patients with CTO were included in a registry to be followed for about 10 years.

Patients who had previously undergone a coronary artery bypass were excluded (n=477), leaving 833 patients in whom rechanneling was used as initial treatment strategy, and 664 whose initial treatment was optimal medical therapy.

In both groups, patients with multivessel disease were treated with angioplasty for non-CTO obstructive lesions.


Read also: Should Total Occlusion Influence on Revascularization Strategy?


Within the rechanneling group, success rate was 79.2%. Furthermore, this group presented lower cardiovascular mortality during the 10-year follow-up compared with the optimal medical therapy group (10.4% vs. 22.3%; hazard ratio [HR]: 0.44: 95% confidence interval (CI): 0.32 to 0.59; p < 0.001).

Results were consistent after propensity score matching the baseline characteristics of both populations (13.6% vs. 20.8%; HR: 0.64, 95% CI: 0.45 to 0.91; p = 0.01).

The mortality benefit observed with rechanneling was driven by a separation of the curves observed between 3 and 10 years (8.3% vs. 16.6%; HR: 0.43, 95% CI: 0.27 to 0.71; p < 0.001), but not earlier (5.7% vs. 5.0%; p = 0.71).


Read also: Biodegradable Polymer Myth Also Debunked for ACSs.


The beneficial effects of rechanneling were consistent in all patient subgroups.

Conclusion

Rechanneling a chronic total occlusion as initial treatment strategy may reduce long-term mortality compared with optimal medical therapy. Results from this research need confirmation from similar follow-up in randomized studies.

JAHA-120-019022

Original Title: Late Survival Benefit of Percutaneous Coronary Intervention Compared With Medical Therapy in Patients With Coronary Chronic Total Occlusion: A 10-Year Follow-Up Study.

Reference: Taek Kyu Park et al. J Am Heart Assoc. 2021;10:e019022. DOI: 10.1161/JAHA.120.019022.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

CRABBIS Trial: Comparison of Different Provisional Stenting Sequences

Provisional stenting (PS) is the gold standard for percutaneous coronary intervention (PCI) in most patients with coronary bifurcation lesions (CBL). Moreover, recent studies such...

Andromeda Trial: Meta-Analysis of Drug Coated Balloon vs. DES in Small Vessel DeNovo Lesions

The use of coronary stents vs plain old balloon angioplasty (POBA), has allowed to reduce recoil and limiting flow dissection which were major limitation...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...